Inceptive Raises $100mn to Develop AI-based Vaccines and Drugs in Biotech Expansion
Andreessen Horowitz, which has invested in numerous tech companies, sees Inceptive's approach as the future of drug design. Chris Dixon, a general partner at Andreessen Horowitz, stated, “The blend of biology and AI has enormous potential. It can effectively shorten the drug development cycle, saving years and millions of dollars.